Kazia Therapeutics Limited (KZIA)
KZIA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-06-30, https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/0001193125-25-272284-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-06-30. Converted from AUD at 1.4266 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | KZIA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0001075880 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | C3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $29K |
| Net income | -$14.5M |
| Operating income | Not in SEC XBRL data |
| Net margin | -49290.5% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4246.3× |
Reported in AUD; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B3 | 2026-09-22 |
| Latest annual report | 20-F | 2025-11-07 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-09-22 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OGI | Organigram Global Inc. Common Shares | $0.9190 | -1.68% | $129.6M |
| KRRO | Korro Bio Inc. | $8.81 | -5.98% | $129.7M |
| NERV | Minerva Neurosciences Inc | $2.52 | -12.98% | $120.1M |
| RNA | Atrium Therapeutics Inc. | $7.75 | -5.60% | $132.6M |
| NRXP | NRX Pharmaceuticals Inc. | $2.70 | -5.26% | $116.9M |
| SPRB | Spruce Biosciences Inc. | $40.35 | -5.88% | $116.0M |
| PDSB | PDS Biotechnology Corporation | $1.60 | +5.26% | $116.0M |
| ALXO | ALX Oncology Holdings Inc. | $0.9796 | -22.25% | $135.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier